- Report
- April 2024
- 280 Pages
Global
From €3525EUR$3,570USD£2,944GBP
- Report
- May 2023
- 268 Pages
Global
From €3525EUR$3,570USD£2,944GBP
- Report
- April 2023
- 250 Pages
Global
From €3525EUR$3,570USD£2,944GBP
- Report
- April 2023
- 374 Pages
Global
From €3525EUR$3,570USD£2,944GBP
- Report
- February 2023
- 213 Pages
Global
From €3525EUR$3,570USD£2,944GBP
- Report
- November 2022
- 335 Pages
Global
From €3525EUR$3,570USD£2,944GBP
- Report
- October 2022
- 243 Pages
Global
From €3525EUR$3,570USD£2,944GBP
- Report
- October 2022
- 275 Pages
Global
From €3525EUR$3,570USD£2,944GBP
- Report
- February 2021
- 225 Pages
Global
From €3413EUR$3,456USD£2,850GBP
- Report
- December 2019
- 222 Pages
Global
From €5303EUR$5,370USD£4,428GBP
- Book
- March 2022
- 992 Pages
- Book
- April 2010
- 360 Pages
- Book
- January 2010
- 616 Pages
- Book
- January 2018
- 344 Pages
- Book
- March 2015
- 512 Pages
- Book
- August 2014
- 392 Pages
- Book
- February 2012
- 1096 Pages
- Book
- October 2010
- 408 Pages
The Cardiovascular Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cardiovascular diseases. These drugs are used to treat conditions such as hypertension, coronary artery disease, congestive heart failure, and arrhythmias. Cardiovascular drugs are also used to reduce the risk of stroke, heart attack, and other cardiovascular events.
The market is composed of a variety of companies, ranging from large multinationals to small start-ups. Major players in the market include Pfizer, Merck, Novartis, Sanofi, and Bristol-Myers Squibb. These companies are involved in the research, development, and production of cardiovascular drugs. Additionally, there are a number of smaller companies that specialize in the production of generic cardiovascular drugs. These companies include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more